🏛️ Verified NIH Record • Updated 2025-11-05
Adjuvant Treatment Determined By Pathological Response To Neoadjvuant Nivolumab (NCT04013854)
Adjuvant Nivolumab or Ipilimumab + Nivolumab Determined By Pathological Response To A Single Dose Of Neoadjvuant Nivolumab
🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic Sponsor: Abramson Cancer Center at Penn Medicine
🩺 Plain-English Summary (8th-Grade Level)
Subjects with resectable melanoma will receive neoadjuvant nivolumab followed by surgical resection. Post-operatively, subjects will receive open-label treatment with up to 1 year of adjuvant nivolumab or ipilimumab plus nivolumab as determined by pathologic response at the time of resection.
Who can join: Review the eligibility criteria below.
Location: Duke Cancer Institute — Durham, North Carolina
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (3 Sites)
- Duke Cancer Institute — Durham, North Carolina
- Lancaster General Hospital — Lancaster, Pennsylvania
- Abramson Cancer Center, University of Pennsylvania — Philadelphia, Pennsylvania
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Melanoma Stage III
- Infliximab for Treatment of Immune Checkpoint Inhibitor Colitis — Boston, Massachusetts
- SX-682 Treatment in Subjects With Metastatic Melanoma Concurrently Treated With Pembrolizumab — Miami, Florida
- Neoadjuvant PD-1 Inhibitor Dostarlimab (TSR-042) vs. Combination of Tim-3 Inhibitor Cobolimab (TSR-022) and PD-1 Inhibitor Dostarlimab (TSR-042) in Melanoma — Washington D.C., District of Columbia
- Binimetinib and Imatinib for Unresectable Stage III-IV KIT-Mutant Melanoma — La Jolla, California
- Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma — Tampa, Florida
Explore by condition: All Melanoma Stage III clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.